Filtering options
Pharma
MedTech
EU
US
M&A
CDD/VDD
Asia-Pac
Biotech
CDMO
2022
Pharma
EU
Daiichi-Sankyo Europe sells to Substipharm
The sale of a non-strategic asset to Substipharm, will allow Daiichi Sankyo to repurpose its financial and operational resources on other value added products by developing and sourcing innovative products with strong competitive advantage in oncology.
2022
Pharma
EU
Biotech
Exclusive sell-side advisor: Formycon acquires Biosimilar Assets from ATHOS KG
Formycon has completed the full acquisition of biosimilar candidate FYB202 (ustekinumab) and acquisition of a 50% stake in biosimilar candidate FYB201 (ranibizumab) as well as the takeover of the operational development unit Bioeq GmbH. Alira Health acted as the sell-side advisor to the sellers.
2022
MedTech
EU
CDMO
Exclusive sell-side advisor: GVS acquires Haemotronic
GVS has finalized the acquisitions of Haemotronic, a company specializing in medical device components and products. Alira Health represented the sellers in the transaction, which establishes an Italy-based, global leader of specialty manufacturing solutions to the healthcare and life sciences markets.
2022
Pharma
US
CDMO
Exclusive buy-side advisor: Asahi Kasei acquires Bionova Scientific
Asahi Kasei Medical has finalized the acquisition of Bionova Scientific, a company specializing in contract development and GMP-compliant manufacturing services for biopharmaceutical companies. Alira Health represented the buyer in the transaction, contributing unique know-how of drug development, quality, and operations that was critical for the deal completion.
2022
MedTech
US
M&A
Exclusive sell-side advisor: Trelleborg acquires EirMed
Trelleborg Group has finalized the acquisition of EirMed, LLC, a company specializing in technical precision plastic injection-molded components for medical devices, including in-vitro diagnostics, minimally invasive surgery, and orthopedics. Alira Health represented the sellers in the transaction, playing a key role in managing the process and leading the deal to success.
2022
Pharma
EU
Biotech
Exclusive transaction advisor: several out-licensing agreements for EQL Pharma’s Mellozzan in Europe
Alira Health supported EQL Pharma on entering into several licensing agreements with renowned pharmaceutical companies with strong a presence the providing important medicines for the treatment of ADHD.
2020
MedTech
EU
M&A
Strategic advisor: BENVIC acquires LUC & BEL
With the acquisition of Luc & Bel, Benvic further strengthens its position in the medical sector. Luc & Bel is an Italian company specializing in the design and manufacturing of medical device components. Luc & Bel is now well-positioned to accelerate its growth with the many synergies and international presence of Benvic.
2020
Pharma
EU
M&A
Advisor: Sagard NewGen invests in Laboratoires Delbert
Laboratoires Delbert’s recent capital raise of €40m supports its growth strategy and mission of keeping essential medicinal products on the market and available to patients around the world. Alira Health advised Sagard NewGen on this equity investment.